Targeting mitochondria: a novel approach for treating platinum-resistant ovarian cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Targeting mitochondria: a novel approach for treating platinum-resistant ovarian cancer ; volume:22 ; number:1 ; day:25 ; month:10 ; year:2024 ; pages:1-13 ; date:12.2024
Journal of translational medicine ; 22, Heft 1 (25.10.2024), 1-13, 12.2024
- Urheber
-
Cui, Xin
Xu, Juan
Jia, Xuemei
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12967-024-05770-y
- URN
-
urn:nbn:de:101:1-2501152119143.716969622558
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cui, Xin
- Xu, Juan
- Jia, Xuemei
- SpringerLink (Online service)
Ähnliche Objekte (12)
Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer
Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer
AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin
Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer
High-expressed ACAT2 predicted the poor prognosis of platinum-resistant epithelial ovarian cancer
New Platinum(II) Complexes Affecting Different Biomolecular Targets in Resistant Ovarian Carcinoma Cells
Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer
Targeting SOD1 via RNAi with PEGylated graphene oxide nanoparticles in platinum-resistant ovarian cancer
Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer
The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer
Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer
Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer
AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin
Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer
High-expressed ACAT2 predicted the poor prognosis of platinum-resistant epithelial ovarian cancer
New Platinum(II) Complexes Affecting Different Biomolecular Targets in Resistant Ovarian Carcinoma Cells
Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer
Targeting SOD1 via RNAi with PEGylated graphene oxide nanoparticles in platinum-resistant ovarian cancer
Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer
The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer
Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer
Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer
AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin
Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer
High-expressed ACAT2 predicted the poor prognosis of platinum-resistant epithelial ovarian cancer
New Platinum(II) Complexes Affecting Different Biomolecular Targets in Resistant Ovarian Carcinoma Cells
Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer
Targeting SOD1 via RNAi with PEGylated graphene oxide nanoparticles in platinum-resistant ovarian cancer
Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer